EGFR-TKI治疗对NSCLC患者血清CEA的影响

Effect of EGFR-TKI on serum CEA in patients with NSCLC

目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗对非小细胞肺癌(NSCLC)患者血清癌胚抗原(CEA)的影响。方法选取NSCLC患者81例,均接受EGFR-TKI治疗,监测患者治疗前后的CEA水平。结果完全缓解(CR)+部分缓解(PR)患者治疗后的CEA水平低于治疗前(P﹤0.05);进展(PD)患者治疗后的CEA水平高于治疗前(P﹤0.05);稳定(SD)患者治疗前后的CEA水平比较,差异无统计学意义(P﹥0.05);CR+PR患者治疗前的CEA水平高于SD和PD患者(P﹤0.05);不同年龄、性别、吸烟史、组织类型、临床分期和治疗药物的NSCLC患者的近期疗效比较,差异无统计学意义(P﹥0.05);基线CEA≥5 ng/ml患者的近期疗效优于基线CEA﹤5 ng/ml的患者(P﹤0.05);基线CEA≥5 ng/ml组患者的中位无疾病进展时间为16.61个月(95%CI:12.22~20.43个月),长于基线CEA﹤5 ng/ml组患者的9.82个月(95%CI:5.21~14.40个月)(P﹤0.05)。结论血清CEA监测有助于判断NSCLC患者EGFR-TKI治疗效果,CEA治疗前高水平可能预示靶向药物治疗效果好。

Objective To investigate the effect of epidermal growth factor receptor tyrosine kinase inhibitor（EGFRTKI） on serum carcinoembryonic antigen（CEA） in patients with non-small cell lung cancer（NSCLC）. Method 81 patients with NSCLC were included in the study, and all patients were treated with EGFR-TKI, the level of CEA were monitored before and after treatment. Result After treatment, the CEA level in patients with complete remission（CR） or partial remission（PR） was significantly lower than before treatment（P〈0.05）; patients with progressive disease（PD） had higher CEA after treatment than before treatment（P〈0.05）; the CEA level was similar before and after treatment in patients with stable disease（SD）（P〈0.05）; higher CEA level before treatment was observed in patients with CR＋PR compared to those with SD and PD（P〈0.05）; short-term efficacy was consistent in patients of different age, gender, smoking history, histological type, clinical stage, and medication administered（P〈0.05）; the short-term efficacy was better in patients with baseline CEA≥5 ng/ml than those with baseline CEA〈5 ng/ml（P〈0.05）; the median progression-free survival（PFS） in baseline CEA≥5 ng/ml group was 16.61 months（95%CI： 12.22-20.43 months）, which was significantly longer than the baseline CEA〈5 ng/ml group at 9.82 months（95% CI： 5.21-14.40 months）（P〈0.05）. Conclusion Serum CEA monitoring is helpful in evaluating the therapeutic effect of EGFR-TKI in NSCLC patients, and higher CEA level before treatment may indicate a good effect of targeted medication.